Search our extensive Laboratory Test Directory to find test codes, ordering recommendations, specimen stability information, Test Fact Sheets, and more.
Recommendations when to order or not order the test. May include related or preferred tests.
Use to confirm a diagnosis of familial cerebral cavernous malformation (FCCM) in an individual with suggestive findings.
New York DOH Approval Status
Indicates test has been approved by the New York State Department of Health.
Testing is not New York state approved. Specimens from New York clients will be sent out to a New York state-approved laboratory.
Specimen Required
Patient PreparationInstructions patient must follow before/during specimen collection.
CollectSpecimen type to collect. May include collection media, tubes, kits, etc.
Lavender or pink (EDTA) or yellow (ACD solution A or B) New York State Clients: Lavender (EDTA)
Specimen PreparationInstructions for specimen prep before/after collection and prior to transport.
Transport 3 mL whole blood. (Min: 3 mL)
Storage/Transport TemperaturePreferred temperatures for storage prior to and during shipping to ARUP. See Stability for additional info.
Refrigerated.
Unacceptable ConditionsCommon conditions under which a specimen will be rejected.
Serum or plasma; grossly hemolyzed or frozen specimens; saliva, buccal brush, or swab; FFPE tissue.
RemarksAdditional specimen collection, transport, or test submission information.
StabilityAcceptable times/temperatures for specimens. Times include storage and transport time to ARUP.
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable New York State Clients: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: Unacceptable
Methodology
Process(es) used to perform the test.
Massively Parallel Sequencing
Performed
Days of the week the test is performed.
Varies
Reported
Expected turnaround time for a result, beginning when ARUP has received the specimen.
10-15 days
Reference Interval
Normal range/expected value(s) for a specific disease state. May also include abnormal ranges.
By report
Interpretive Data
May include disease information, patient result explanation, recommendations, or details of testing.
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
Compliance Category
Laboratory Developed Test (LDT)
Note
Additional information related to the test.
Genes tested: CCM2*, KRIT1, PDCD10 * - One or more exons are not covered by deletion/duplication analysis; see additional technical information.
The American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ. CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
Other names that describe the test. Synonyms.
cavernomas
CCM
CCM1/KRIT1, CCM2, CCM3/PDCD10
Cerebral cavernous angioma
familial CCM
Cerebral Cavernous Malformation Panel, Sequencing and Deletion/Duplication
Connect Sign In
